Skip to main content
. Author manuscript; available in PMC: 2012 Jul 1.
Published in final edited form as: Trends Mol Med. 2011 Mar 24;17(7):380–388. doi: 10.1016/j.molmed.2011.02.004

Fig. 2. An example of the clinical relevance of dogs for cancer treatments.

Fig. 2

Canines are increasingly being used in clinical cancer drug trials to determine the efficacy of treatment given how closely many of the cancer they develop recapitulate the human cancer. (A) A picture of a Boston terrier, a breed predisposed to the development of Mast cell tumors. (B) London et al. conducted a clinical trial of an oral receptor tyrosine kinase inhibitor, Palladia on dogs with recurrent mast cell tumors. Shown here is a Kaplan-Meier survival analysis demonstrating time to tumor progression in placebo-treated and Palladia-treated dogs with Mast Cell Tumors [75]. (C) A breakdown of the clinical trial of Palladia, including the demonstrated advantages of dogs as models of pharmacologic cancer intervention. Reproduced with Permission, from [75].